Actavia Life Sciences, Inc.
RASP · OTC
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
|---|---|---|---|---|
| Market Cap | $6,020 | $5,943 | $11,560 | $19,218 |
| - Cash | $1 | $19 | $75 | $2 |
| + Debt | $304 | $226 | $211 | $216 |
| Enterprise Value | $6,323 | $6,149 | $11,696 | $19,431 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$71 | -$124 | -$10 | $0 |
| % Margin | – | – | – | – |
| Net Income | -$96 | -$148 | -$58 | -$105 |
| % Margin | – | – | – | – |
| EPS Diluted | -0 | -0 | -0 | -0 |
| % Growth | 50% | -100% | 0% | – |
| Operating Cash Flow | -$36 | -$47 | $7 | $10 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$36 | -$47 | $7 | $10 |